Literature DB >> 28409283

Body composition and lung function in children with cystic fibrosis and meconium ileus.

Artemis Doulgeraki1, Argyri Petrocheilou2, Glykeria Petrocheilou1, George Chrousos2, Stavros-Eleftherios Doudounakis2, Athanasios G Kaditis3.   

Abstract

The aim of this study was to explore whether history of meconium ileus (MI) at birth in children and adolescents with cystic fibrosis (CF) adversely affects body composition and lung function in later life. Data of children and adolescents with CF who underwent spirometry and DXA as part of their routine care were analyzed. Associations between MI (explanatory variable) and areal bone mineral density (total body less head-TBLH aBMD), lean tissue mass (LTM), and fat mass (FM) (outcomes) were assessed using general linear models. Potential relationships of TBLH aBMD, LTM, and FM with FEV1 (additional outcome) were also explored. One hundred and one subjects with CF (mean age 14 ± 3 years) were included, 19 (18.8%) of whom had history of MI. Negative associations were demonstrated between history of MI and FEV1 (P = 0.04), TBLH aBMD (P = 0.03), and FM (P < 0.01) but not between history of MI and LTM (P = 0.07) after adjustment for other variables. Lung function was positively associated with TBLH aBMD (P < 0.01) and LTM (P = 0.02) but not with FM (P = 0.20).
CONCLUSION: Among children and adolescents with CF, those with history of MI have lower bone mineral density, FM, and lung function. What is Known: • Among children and adolescents with cystic fibrosis, those with history of meconium ileus in the neonatal period are at risk of having lower body mass index percentile and FEV 1 percent predicted. What is New: • Children and adolescents with cystic fibrosis and history of meconium ileus have decreased bone mineral density and fat mass compared to patients without such history. • Lower lung function in children with MI coexists with suboptimal bone mineral density.

Entities:  

Keywords:  Body composition; Cystic fibrosis; Lung function; Meconium ileus

Mesh:

Year:  2017        PMID: 28409283     DOI: 10.1007/s00431-017-2906-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  35 in total

1.  Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis.

Authors:  H M Buntain; P J Schluter; S C Bell; R M Greer; J C H Wong; J Batch; P Lewindon; C E Wainwright
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

2.  The impact of meconium ileus on the clinical course of children with cystic fibrosis.

Authors:  A K Evans; D A Fitzgerald; K O McKay
Journal:  Eur Respir J       Date:  2001-11       Impact factor: 16.671

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Clinical course of patients with cystic fibrosis presenting with meconium ileus.

Authors:  J A Coutts; J G Docherty; R Carachi; T J Evans
Journal:  Br J Surg       Date:  1997-04       Impact factor: 6.939

5.  Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus.

Authors:  E Kerem; M Corey; B Kerem; P Durie; L C Tsui; H Levison
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

6.  Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Authors:  Melissa S Putman; Joshua F Baker; Ahmet Uluer; Karen Herlyn; Allen Lapey; Leonard Sicilian; Angela Pizzo Tillotson; Catherine M Gordon; Peter A Merkel; Joel S Finkelstein
Journal:  J Cyst Fibros       Date:  2015-02-16       Impact factor: 5.482

7.  Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.

Authors:  M Proesmans; W Balinska-Miskiewicz; L Dupont; X Bossuyt; J Verhaegen; N Høiby; K de Boeck
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

8.  Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.

Authors:  Theodore G Dassios; Anna Katelari; Stavros Doudounakis; Gabriel Dimitriou
Journal:  Respir Care       Date:  2013-08-27       Impact factor: 2.258

9.  Long-term pulmonary outcome after meconium ileus in cystic fibrosis.

Authors:  Matthias Kappler; Maria Feilcke; Christian Schröter; Angelika Kraxner; Matthias Griese
Journal:  Pediatr Pulmonol       Date:  2009-12

10.  Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study.

Authors:  Vincenzina Lucidi; Federico Alghisi; Valeria Raia; Beatrice Russo; Lauretta Valmarana; Rossella Valmarana; Anna Coruzzo; Stefano Beschi; Silvia Dester; Daniela Rinaldi; Marica Maglieri; Maria L Guidotti; Emanuela Ravaioli; Marisa Pesola; Alessandra De Alessandri; Rita Padoan; Luigi Grynzich; Luigi Ratclif; Teresa Repetto; Maura Ambroni; Ettore Provenzano; Alberto E Tozzi; Carla Colombo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-09       Impact factor: 2.839

View more
  2 in total

1.  HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge.

Authors:  Julie Rosenjack; Craig A Hodges; Rebecca J Darrah; Thomas J Kelley
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

2.  Association of bone mineral density with lung function in a Chinese general population: the Xinxiang rural cohort study.

Authors:  Xiang Zeng; Dongling Liu; Xiangmei Zhao; Ling Chao; Yuchun Li; Huijun Li; Wen Li; Lihui Gui; Weidong Wu
Journal:  BMC Pulm Med       Date:  2019-12-09       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.